podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 15/22 Podcast
  4. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.
Background: cJun terminal kinase (JNK) is constitutively activated
in most hepatocellular carcinomas (HCCs), yet its exact role in
carcinogenesis remains controversial. While tumour necrosis factor
(TNF)-related apoptosisinducing ligand (TRAIL) is known as a major
mediator of acquired immune tumour surveillance, and is currently
being tested in clinical trials as a novel cancer therapy, the
resistance of many tumours to TRAIL and concerns about its toxicity
in vivo represent obstacles to its clinical application. In this
study we investigated whether JNK activity in HCC could contribute
to the resistance to apoptosis in these tumours. Methods: The
effect of JNK/Jun inhibition on receptormediated apoptosis was
analysed by pharmacological inhibition or RNA interference in
cancer cells and nontumour cells isolated from human liver or
transgenic mice lacking a phosphorylation site for Jun. Results:
JNK inhibition caused cell cycle arrest, enhanced caspase
recruitment, and greatly sensitised HCC cells but not normal
hepatocytes to TRAIL. TRAILinduced activation of JNK could be
effectively interrupted by administration of the JNK inhibitor
SP600125. Conclusions: Expression and TRAIL-dependent feedback
activation of JNK likely represent a mechanism by which cancer
cells escape TRAIL-mediated tumour surveillance. JNK inhibition
might represent a novel strategy for specifically sensitising HCC
cells to TRAIL thus opening promising therapeutic perspectives for
safe and effective use of TRAIL in cancer treatment.

Weitere Episoden

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

vor 17 Jahren
Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

vor 17 Jahren
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

vor 17 Jahren
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

vor 17 Jahren
Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis

Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis

vor 17 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz